Progenics (PGNX) Said RELISTOR Clinical Trials Initiated in Japan
More News related to PGNX
- Progenics Announces Third Quarter 2009 Financial Results
- BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals
- Lazard Capital Upgrades Progenics Pharmaceuticals (PGNX) to Buy
- Lazard Capital Upgrades Progenics Pharmaceutical (PGNX) to Buy
- Needham Cuts Progenics (PGNX) to Hold Midday
More News related to WYE
- Progenics Announces Third Quarter 2009 Financial Results
- Pfizer (PFE) Completes Acquisition of Wyeth (WYE)
- Pfizer Completes Acquisition Of Wyeth
- U.S. antitrust regulators cleared the Pfizer (PFE), Wyeth (WYE) merger
- Progenics Pharma (PGNX) Regains RELISTOR Rights from Wyeth (WYE)
More News related to FDA
- Maidenform Brands (MFB) Reports Mixed Q3 Earnings; Guides Q4, Raises FY09 Outlook
- ZOLL Medical (ZOLL) Posts Q4 EPS of $0.16, Tops by 8c
- Emdeon (EM) Tops Q3 EPS by 2c; Guides In-line for FY09
- GlobalScape (GSB) Posts Q3 EPS of $0.03, Tops Q308 EPS by 2c
- Progressive Corporation (PGR) Reports October '09 Results
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced that its collaborator, Ono Pharmaceutical Co., Ltd., has begun clinical testing in Japan of RELISTOR subcutaneous injection, the first-in-class medicine approved in the U.S., Canada, the European Union, Australia and Latin American countries for the treatment of opioid-induced constipation.
Ono has exclusive rights to subcutaneous RELISTOR in Japan, where it is pursuing plans to develop and commercialize the drug, designated ONO-3849, for the treatment of opioid-induced constipation.
RELISTOR is being developed and commercialized in the rest of the world by Progenics and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).
Related Categories
FDAStocks Mentioned
-0.18
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
